News Bell: Enterprise Products Partners L.P. (NYSE:EPD), Novavax, Inc. (NASDAQ:NVAX)

98
u.s stocks

Enterprise Products Partners L.P. (NYSE:EPD)

The company announced its last quarter financial performance results on 10/27/2016. Enterprise Products Partners L.P. (NYSE:EPD) belongs to Oils-Energy sector that surged 0.27% in value when last trading session closed at $25.98. The company has a market capitalization of $54.71 Billion. The company’s stock has a Return on Assets (ROA) of 5 percent, a Return on Equity (ROE) of 11.9 percent and Return on Investment (ROI) of 8.3 percent. The company reached its 52-Week high of $30.11 on Jul 14, 2016 and 52-Week low of $19 on Jan 20, 2016.

Earnings per share (ttm) for Enterprise Products Partners L.P. (NYSE:EPD) according to Finviz Data is $1.23.

The growth estimate for Enterprise Products Partners L.P. (NYSE:EPD) for the current quarter is -5.9 percent. The projected growth estimate for the next quarter is 3.1 percent. The company’s stock has grown by -1.11 percent in the past 5 years. For the next 5 years, the company is expected to grow by 5.65 percent.

This company was Initiated by Ladenburg Thalmann on 16-Nov-16  to Buy.

The 28 analysts offering 12-month price forecasts for Enterprise Products Partners LP have a median target of 32.00, with a high estimate of 36.00 and a low estimate of 26.00. The median estimate represents a +23.17% increase from the last price of 25.98.

Financial History:

Following Earnings result, share price were UP 16 times out of last 27 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 33% percent of times. It has met expectations  4  times and missed earnings  4  times.

The consensus recommendation for Enterprise Products Partners L.P. (NYSE:EPD) is 1.1. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.17. In comparison, the consensus recommendation 60 days ago was at 1.17, and 90 days ago was at 1.19 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Enterprise Products Partners L.P. to have earnings per share of $0.32.

Revenue is expected to range from 5.43 Billion to 6.43 Billion with an average of 5.97 Billion.

Company Profile:

Enterprise Products Partners L.P. is a leading integrated provider of processing and transportation services to producers of Natural Gas Liquids (NGLs) and consumers of NGL products. The Company fractionates for a processing fee mixed NGLs produced as by-products of oil and natural gas production into their component products: ethane, propane, isobutane, normal butane and natural gasoline; converts normal butane to isobutane through the process of isomerization; produces MTBE from isobutane and methanol; and transports NGL products to end users by pipeline and railcar.

Novavax, Inc. (NASDAQ:NVAX):

Novavax, Inc. (NASDAQ:NVAX) belongs to Medical sector closed its last session with a gain of 0 percent and closed its previous trading session at $1.4. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $-1.12. The company has the Market capitalization of $379.49 Million. The company’s stock has a Return on Assets (ROA) of -61.5 percent, a Return on Equity (ROE) of -189.1 percent and Return on Investment (ROI) of -53.6 percent. The company reached its 52-Week high of $8.74 on Dec 29, 2015 and 52-Week low of $1.16 on Sep 16, 2016.

This company was Downgrade by Citigroup on 16-Sep-16 to Neutral.

The 6 analysts offering 12-month price forecasts for Novavax Inc have a median target of 1.50, with a high estimate of 12.00 and a low estimate of 1.50. The median estimate represents a +7.14% increase from the last price of 1.40.

Financial History:

Following Earnings result, share price were DOWN 18 times out of last 27 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 25% percent of times. It has met expectations  3  times and missed earnings  6  times.

The consensus recommendation for Novavax, Inc. (NASDAQ:NVAX) is 2.67. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 2.67. In comparison, the consensus recommendation 60 days ago was at 2.67, and 90 days ago was at 2.67 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Novavax, Inc. to have earnings per share of $-0.23.

Revenue is expected to range from 3.5 Million to 9 Million with an average of 5.25 Million.

Company Profile:

NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants.

-